Tower Research Capital LLC (Trc) Kal Vista Pharmaceuticals, Inc. Transaction History

Tower Research Capital LLC (Trc)

$3.68 Billion
Q3 2024

A detailed history of Tower Research Capital LLC (Trc) transactions in Kal Vista Pharmaceuticals, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 825 shares of KALV stock, worth $6,476. This represents 0.0% of its overall portfolio holdings.

Number of Shares

825

Previous 3,691 77.65%

Holding current value

$6,476

Previous $43,000 79.07%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$9.46 - $15.39 $27,112 - $44,107	-2,866 Reduced 77.65%	825 $9,000
Q2 2024 Aug 13, 2024	BUY	$10.35 - $12.49 $36,483 - $44,027	3,525 Added 2123.49%	3,691 $43,000
Q1 2024 May 15, 2024	SELL	$11.07 - $16.04 $36,708 - $53,188	-3,316 Reduced 95.23%	166 $1,000
Q4 2023 Feb 13, 2024	BUY	$7.58 - $12.25 $5,821 - $9,408	768 Added 28.3%	3,482 $42,000
Q3 2023 Nov 14, 2023	BUY	$8.95 - $11.35 $7,822 - $9,919	874 Added 47.5%	2,714 $26,000
Q2 2023 Aug 14, 2023	BUY	$7.73 - $10.57 $6,230 - $8,519	806 Added 77.95%	1,840 $16,000
Q1 2023 May 09, 2023	SELL	$6.3 - $8.39 $7,925 - $10,554	-1,258 Reduced 54.89%	1,034 $8,000
Q4 2022 Feb 10, 2023	BUY	$4.2 - $14.24 $1,419 - $4,813	338 Added 17.3%	2,292 $15,000
Q3 2022 Nov 10, 2022	SELL	$9.85 - $16.83 $1,625 - $2,776	-165 Reduced 7.79%	1,954 $29,000
Q2 2022 Aug 15, 2022	SELL	$8.16 - $15.1 $563 - $1,041	-69 Reduced 3.15%	2,119 $21,000
Q1 2022 May 12, 2022	BUY	$11.2 - $16.97 $16,811 - $25,471	1,501 Added 218.49%	2,188 $32,000
Q4 2021 Feb 14, 2022	SELL	$12.36 - $18.28 $2,200 - $3,253	-178 Reduced 20.58%	687 $9,000
Q3 2021 Nov 15, 2021	SELL	$17.11 - $24.49 $98,142 - $140,474	-5,736 Reduced 86.9%	865 $15,000
Q2 2021 Aug 16, 2021	BUY	$23.12 - $29.91 $67,441 - $87,247	2,917 Added 79.18%	6,601 $158,000
Q1 2021 May 17, 2021	BUY	$14.69 - $42.57 $146 - $425	10 Added 0.27%	3,684 $95,000
Q4 2020 Feb 16, 2021	SELL	$12.88 - $19.47 $145,505 - $219,952	-11,297 Reduced 75.46%	3,674 $70,000
Q3 2020 Nov 16, 2020	BUY	$9.83 - $13.99 $12,896 - $18,354	1,312 Added 9.61%	14,971 $188,000
Q2 2020 Aug 13, 2020	BUY	$6.75 - $12.89 $92,198 - $176,064	13,659 New	13,659 $165,000
Q4 2019 Feb 07, 2020	SELL	$10.31 - $17.81 $39,971 - $69,049	-3,877 Closed	0 $0
Q3 2019 Nov 05, 2019	BUY	$11.6 - $21.67 $42,746 - $79,853	3,685 Added 1919.27%	3,877 $45,000
Q2 2019 Aug 13, 2019	BUY	$18.44 - $30.89 $2,913 - $4,880	158 Added 464.71%	192 $4,000
Q1 2019 May 14, 2019	SELL	$16.51 - $31.1 $2,113 - $3,980	-128 Reduced 79.01%	34 $1,000
Q4 2018 Feb 14, 2019	SELL	$16.21 - $24.06 $25,611 - $38,014	-1,580 Reduced 90.7%	162 $4,000
Q3 2018 Nov 13, 2018	BUY	$8.0 - $22.11 $11,312 - $31,263	1,414 Added 431.1%	1,742 $39,000
Q2 2018 Aug 15, 2018	SELL	$7.79 - $9.84 $7,423 - $9,377	-953 Reduced 74.4%	328 $3,000
Q1 2018 May 15, 2018	BUY	$9.22 - $12.35 $4,066 - $5,446	441 Added 52.5%	1,281 $12,000
Q4 2017 Feb 09, 2018	BUY	$6.8 - $13.54 $5,712 - $11,373	840	840 $8,000

Others Institutions Holding KALV

# of Institutions

125

Shares Held

47.8M

Call Options Held

551K

Put Options Held

110K

View Full List

About KalVista Pharmaceuticals, Inc.

Ticker KALV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,602,000
Market Cap $193M
Description
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...

More about KALV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.

Account

Tower Research Capital LLC (Trc) Kal Vista Pharmaceuticals, Inc. Transaction History